Sun Pharmaceutical Industries Limited, announced that one of its wholly-owned subsidiaries launched a novel anti-cancer drug in India, Palbociclib. This drug is for patients who have advanced breast cancer, the most common type of cancer among women in the country.
The company will make the drug available under the brand name PALENOTM (Palbociclib) in 75mg, 100mg and 125mg.
The drug is approved by the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA) and Central Drugs Standard Control Organisation (CDSCO) in combination with hormonal therapies for patients with hormone receptor-positive, Human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer.
Kirti Ganorkar, CEO– India Business, Sun Pharma, said “We are introducing Palbociclib at an affordable price which will help improve patient access. PALENO will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility.”
Sun pharmaceutical Ltd is India’s top pharmaceutical company and World’s fourth largest speciality Generic pharmaceutical company.
